Home > Healthcare > Pharmaceuticals > Finished Drug Form > RNA Therapeutics Market

RNA Therapeutics Market Share

Report ID: GMI8053
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

RNA Therapeutics Market Share

The global RNA therapeutics industry is characterized by the active participation of key pharmaceutical companies and biotech firms. Leading players such as Moderna Inc., Novartis AG, and Pfizer Inc. have established themselves as major contributors to the market. These players are constantly engaging in strategic initiatives such as collaborations, partnerships, and R&D activities to again competitive advantage in the market.

RNA Therapeutics Market Companies

Foremost players operating in the RNA therapeutics industry are as mentioned below:

Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
BioNTech SE
Ionis Pharmaceuticals
Moderna Inc.
Novartis AG
Orna Therapeutics, Inc.
Pfizer Inc.
Sanofi
Sarepta Therapeutics, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global RNA therapeutics industry was valued at USD 19.2 billion in 2023 and is estimated to grow at a CAGR of 5.7% during the forecast period to reach USD 31.1 billion by 2032, owing to the rising incidences of infectious diseases.

The vaccines segment held largest market share of 71.7% in 2023, attributed to the ability of RNA vaccines to induce robust and specific immune responses.

In 2023, North America held a significant share of 36% in the global RNA therapeutics industry, favored by robust R&D initiatives, along with strategic collaborations between pharmaceutical companies and research institutions.

Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., BioNTech SE, Ionis Pharmaceuticals, Moderna Inc., Novartis AG, Orna Therapeutics, Inc., Pfizer Inc., Sanofi and Sarepta Therapeutics, Inc.